INTERCEPT kit utilization rates at existing blood center customers (volume growth from deeper penetration vs new account additions)
Geographic expansion milestones: regulatory approvals in new countries (China, Japan submissions pending), national health system adoption decisions (tender wins in Middle East, Asia)
Red blood cell system adoption trajectory: RBC represents largest addressable market (~40% of transfused components) but slower adoption than platelets/plasma due to operational complexity
Partnership announcements and royalty revenue acceleration from strategic collaborations with national blood operators
low - Blood transfusion volumes are non-discretionary healthcare expenditures driven by surgical procedures, trauma care, and chronic disease management rather than economic cycles. However, elective surgery volumes (which drive ~40% of transfusion demand) can decline modestly during recessions. Hospital capital budgets for blood center equipment may face pressure during healthcare system financial stress, potentially delaying new account additions but not affecting recurring kit revenue from installed base.
Rising rates create moderate headwinds through two channels: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting CERS given negative earnings and 2026 profitability timeline. (2) Hospital and blood center capital allocation becomes more conservative as borrowing costs increase, potentially extending sales cycles for new account wins. However, the recurring revenue model and non-discretionary nature of blood safety provide some insulation. Current 1.60x debt/equity suggests manageable refinancing risk, though cash burn requires monitoring if capital markets tighten.
Regulatory dependency: Revenue growth contingent on country-by-country approvals for each blood component type (platelet, plasma, RBC), with multi-year submission timelines and uncertain outcomes in key markets like China and Japan
Reimbursement pressure: Healthcare cost containment initiatives could pressure blood center budgets, forcing price concessions on disposable kits or delaying capital equipment purchases despite clinical benefits
Alternative pathogen reduction technologies: Competing systems from established medtech players or novel approaches (e.g., UV-C systems, filtration technologies) could erode market share if they demonstrate superior efficacy, lower cost, or easier workflow integration
growth - Investors are attracted to the recurring revenue model, expanding addressable market with RBC system adoption, and inflection toward profitability in 2026. The 66% 3-month and 98% 6-month returns reflect momentum investor participation as the company approaches breakeven. However, negative earnings and execution risk around international expansion require tolerance for volatility and binary regulatory outcomes, appealing to biotech/medtech specialists rather than value investors.
Trend
+21.6% vs SMA 50 · +84.8% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2023 | $170.0M $164.5M–$179.8M | — | -$0.13 | — | ±6% | Low2 |
FY2024 | $199.0M $192.6M–$210.5M | ▲ +17.0% | -$0.12 | — | ±1% | Moderate4 |
FY2025 | $231.0M $223.6M–$244.4M | ▲ +16.1% | -$0.08 | — | ±50% | Low2 |
INSTITUTIONAL OWNERSHIP
CERS News
About
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
CERS◀ | $2.34 | -6.77% | $469M | — | +1434.7% | -758.1% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -3.61% | — | 50.3 | +342054.8% | -3610.2% | 1500 |